Anzeige
Mehr »
Login
Sonntag, 14.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Spezial: Montag letzte Chance vor großer Verkündung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P5G1 | ISIN: US45258J1025 | Ticker-Symbol:
NASDAQ
12.04.24
21:59 Uhr
29,380 US-Dollar
-1,340
-4,36 %
1-Jahres-Chart
IMMUNOVANT INC Chart 1 Jahr
5-Tage-Chart
IMMUNOVANT INC 5-Tage-Chart

Aktuelle News zur IMMUNOVANT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.03.Immunovant and Argenx rise as rival Chugai's data fails to impress13
21.03.Argenx, Immunovant Soar - As Tourmaline Bio Plummets - On A Rival's Lackluster Test Results12
21.03.Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant368BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group...
► Artikel lesen
21.03.WDC, IMVT and TROO are among pre market gainers6
13.03.Goldman Sachs sets $50 target on Immunovant shares, sees upside3
12.03.Immunovant secures patent for autoimmune disease antibody2
12.03.Immunovant Inc.: Immunovant Awarded U.S. Patent for IMVT-1402106Composition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc....
► Artikel lesen
20.02.JPMorgan starts Immunovant with Overweight, sees upside for share price4
15.02.Wolfe Research bullish on Immunovant, sets $55 share price target2
13.02.Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus1
12.02.Recap: Immunovant Q3 Earnings1
12.02.Immunovant GAAP EPS of -$0.36 beats by $0.072
12.02.Immunovant, Inc. - 10-Q, Quarterly Report1
12.02.Immunovant, Inc. - 8-K, Current Report2
12.02.Immunovant Inc.: Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023180Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two fiscal...
► Artikel lesen
22.01.Should You Invest in Immunovant (IMVT)?2
09.01.Immunovant, Inc. - 8-K, Current Report1
26.12.23Immunovant (IMVT) Rose on Positive Clinical Trial3
21.12.23Immunovant stock jumps 9% on positive data for Graves' disease drug1
21.12.23Immunovant Scores Much-Needed Win Following Argenx-Led Sell-Off6
Seite:  Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1